Effect of ATRA on HH, Hut78 and NB4 cells
Cutaneous T-cell lymphoma (CTCL) is a highly heterogeneous non-Hodgkin lymphoma.While retinoids analog including ATRA have been used to treat CTCLs for decades, their mechanism of action and the role of RA-RARa signaling remain poorly understood.Thus,we treated CTCL cells with ATRA.In parallel, we treated acute promyelocytic leukemia (APL) cell line NB4 with ATRA followed by RNA-seq analysis.Total RNA was prepared from biological duplicate plates of cells and subjected to bulk RNAseq. 150-bp paired-end sequencing was performed on the BGISEQ-500. Overall design: HH, Hut78 and NB4 cells were treated with 1 µM of ATRA for 6 hours (n=2 for each group).Total RNA extraction were used for RNA-seq.